Science and Technology Resources

新型亲和试剂的开发。在过去的一年里，科学和技术资源办公室(OSTR)继续支持一项创造高亲和力试剂的倡议，作为分子询问癌症发展过程中改变的途径的工具。与三家生物技术公司(Beckton Dickinson、Pharmingen、Rockland免疫化学公司和表观组学)的合作伙伴关系导致创建了近200种针对CCR感兴趣的数百个关键癌症相关靶点的新型亲和试剂、多克隆和单克隆抗体，而CCR研究人员的成本最低。这些合作伙伴关系为CCR和NCI节省了100多万美元。参与研究的CCR研究人员产生的所有抗体特征数据都通过OSTR和先进生物医学计算中心(ABCC)合作开发的网站提供给相关公司。当抗体发布商业化时，每家公司都会在他们的营销材料中使用这些数据。我们与表观组学的合作伙伴关系是生产兔单克隆抗体。众所周知，这些抗体比鼠单克隆抗体或兔多克隆抗体更稳定，亲和力更高。OSTR与该公司谈判了一项合同，以比目录价格显著降低的成本(5900美元对20000美元)访问他们的抗体生产管道。与其他合作项目类似，CCR调查人员将被要求对抗体进行表征，并为表观组学提供数据，以进行验证和商业化。OSTR正在通过弗雷德里克国家实验室(FNL)的蛋白质表征实验室为CCR研究人员支持哺乳动物细胞中的一些蛋白质相互作用屏幕。OSTR继续评估所有商业上可用的平台、基因表达图谱和其他高通量基因组技术。为了方便CCR研究人员获取最新进展，OSTR已与提供基因组和新陈代谢图谱技术和服务的公司(Affymetrix、NanoString、Agilent、Illumina、Genus、Qiagen、HMT、Metoxon等)建立了一系列安排。这些协议大大降低了成本，并为CCR调查人员提供了一种高效而简单的方式来获取这些技术。已经建立了一项补贴计划，为CCR研究人员获得先进的基因组、蛋白质组、代谢组和生物信息技术提供补贴。这一资助机制帮助延长了CCR实验室可用的有限研究资金，并允许我们的研究人员进行原本可能成本高昂的实验。许多受资助的项目都在顶级期刊上发表了重要文章。最近，OSTR参与了CCR获取下一代测序技术的努力，包括在37号楼建立新的MiSeq核心，任何CCR调查员都可以使用。为了应对CCR迅速增长的管理和分析大量基因组和蛋白质组数据的需求，OSTR与生物信息学公司建立了几个合作伙伴关系。在为NCI节省大量成本的情况下，OSTR代表NCI的所有研究人员谈判了各种许可协议，以普遍获得用于微阵列实验、蛋白质组图谱研究和基因组分析(包括下一代测序数据)的生物信息学和统计分析的尖端工具。此外，OSTR还向所有NCI提供了一些用于研究通路和生物关联网络的软件应用程序。OSTR继续评估CCR在生物信息学和生物统计领域的要求。我们继续与Leidos信息系统计划合作，创建CCR专用生物信息学计划，为CCR调查人员提供支持。通过这一位于贝塞斯达园区的新核心，可以对高通量基因组和蛋白质数据的分析提供支持。

Development of Novel Affinity Reagents. During the past fiscal year, the Office of Science and Technology Resources (OSTR) has continued to support an initiative for generating high affinity reagents to serve as tools for molecular interrogation of pathways that become altered during cancer development. Partnerships with three biotechnology companies (Beckton Dickinson, Pharmingen, Rockland Immunochemicals, and Epitomics) have led to the creation of nearly 200 novel affinity reagents, polyclonal, and monoclonal antibodies against hundreds of key cancer related targets of interest to the CCR at minimal cost to CCR investigators. These partnerships represent savings of more than one million dollars to CCR and the NCI. All of the antibody characterization data generated by participating CCR investigators is made available to the companies involved through a Web site developed in a collaboration between the OSTR and the Advanced Biomedical Computing Center (ABCC). Each company uses this data in their marketing material when the antibodies are released for commercialization. Our partnership with Epitomics is for production of rabbit monoclonal antibodies. These antibodies are known to be much more stable and have higher affinities than mouse monoclonal or rabbit polyclonal antibodies. The OSTR negotiated a contract with the company to access their antibody production pipeline at a significantly reduced cost ($5,900 versus $20,000) from the catalog price. Similar to the other collaborative programs, CCR investigators will be required to characterize the antibodies and make data available to Epitomics for validation and commercialization. The OSTR is supporting a number of protein interaction screens in mammalian cells for CCR investigators through the Laboratory of Protein Characterization at the Frederick National Lab (FNL). The OSTR continues to evaluate all commercially available platforms gene expression profiling and other high throughput genomic technologies. To make the latest advances easily accessible to CCR researchers, the OSTR has established a number of arrangements with companies providing genomic and metabolomic profiling technologies and services (Affymetrix, NanoString, Agilent, Illumina, GenUs, Qiagen, HMT, Metabolon, etc.). These agreements have led to far lower cost and an efficient and easy way for CCR investigators to access these technologies. A subsidy program has been established providing subsidies to support CCR investigator access to advanced genomic, proteomic, metabolomic, and bioinformatic technologies. This funding mechanism has helped to extend the limited research dollars available to CCR laboratories and has permitted our researchers to conduct experiments that might otherwise be cost prohibitive. Many of the funded projects have led to important publications in top tier journals. Most recently, the OSTR has been involved in CCR's efforts to access the next generation sequencing technologies, including the setting up of a new MiSeq Core in building 37, which is available to any CCR investigator. In response to CCR's rapidly growing need to manage and analyze large sets of genomic and proteomic data, the OSTR has developed several partnerships with bioinformatics companies. At significant cost savings to NCI, OSTR negotiated a variety of license agreements on behalf of all NCI researchers for universal access to sophisticated tools for bioinformatic and statistical analysis of microarray experiments, proteomic profiling studies, and genomic analysis including next generation sequencing data. In addition, the OSTR has made a number of software applications for the investigation of pathways and biological association networks available to all of NCI. The OSTR continues to assess CCR's requirements in the area of bioinformatics and biostatistics. We continue to work with the Leidos Information Systems Program to create a CCR dedicated Bioinformatics Program to provide support to CCR investigators. Support for analysis of high throughput genomic and proteomic data is being made available through this new core, which is located on the Bethesda campus.